HR Execs on the Move

BioMarin

www.biomarin.com

 
BioMarin is a global pharmaceutical company focused on developing first-in-class and best-in-class therapeutics that provide meaningful advances to patients who live with serious and life-threatening rare genetic diseases. We remain steadfast to our original mission—to bring new treatments to market that will make a big impact on small patient populations. These patient populations are mostly children, suffering from diseases so rare, that the entire patient population can number as few as 1,000 people worldwide. These conditions are often inherited, difficult to diagnose, progressively debilitating, have few, if any, treatment options and are usually ignored. Time is critical to patients with ...
  • Number of Employees: 1K-5K
  • Annual Revenue: > $1 Billion
  • www.biomarin.com
  • 770 Lindaro Street
    San Rafael, CA USA 94901
  • Phone: 415.506.6700

Executives

Name Title Contact Details
Elena Polansky
Vice President Global Sourcing and Procurement Profile
Erin Burkhart
Group Vice President and Chief Accounting Officer Profile
Humaira Serajuddin
Senior Vice President and Chief Marketing Officer Profile
Trevor Thomas
Associate Director of Threat and Incident Management Profile
Parker Stock
Associate Director, Technical Accounting and Policy Profile

Similar Companies

C3 Jian Inc

C3 Jian Inc is a Inglewood, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

PAR Management

PAR Management is a Newton, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Eurofins Genomics

Eurofins Genomics is an international provider of DNA sequencing services, oligonucleotide synthesis products and bioinformatic services. The company’s strength is its strong customer orientation, fast service and high quality products including a seri...

Accera div Nestle Corp

Accera div Nestle Corp is a Broomfield, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cogent Biosciences

Cogent Biosciences is a biotechnology company developing real solutions to treat genetically driven diseases. With a focus on rational drug discovery and development, we are leveraging validated biology to advance precision therapies designed to address the true underlying drivers of disease and provide real hope for patients. Cogent`s lead therapeutic candidate, PLX9486 (expected to be named CGT9486 in the future), is a precision kinase inhibitor designed to selectively and potently inhibit the KIT D816V mutation. This mutation is responsible for driving a rare and serious condition called Systemic Mastocytosis which can severely impact many different tissues and organs in the body. We are also studying PLX9486 to treat advanced gastrointestinal stromal tumors (GIST), which have a strong dependence on oncogenic KIT signaling.